Review



edta plasma tissue plasminogen activator tpa molecular innovations ipctpakta  (Innovative Research Inc)


Bioz Verified Symbol Innovative Research Inc is a verified supplier
Bioz Manufacturer Symbol Innovative Research Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Innovative Research Inc edta plasma tissue plasminogen activator tpa molecular innovations ipctpakta
    Edta Plasma Tissue Plasminogen Activator Tpa Molecular Innovations Ipctpakta, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 92/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm41693475-83-81-87?v=Innovative+Research+Inc
    Average 92 stars, based on 11 article reviews
    edta plasma tissue plasminogen activator tpa molecular innovations ipctpakta - by Bioz Stars, 2026-07
    92/100 stars

    Images



    Similar Products

    edta plasma tissue plasminogen activator tpa molecular innovations ipctpakta  (Innovative Research Inc)
    92
    Innovative Research Inc edta plasma tissue plasminogen activator tpa molecular innovations ipctpakta
    Edta Plasma Tissue Plasminogen Activator Tpa Molecular Innovations Ipctpakta, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm41693475-83-81-87?v=Innovative+Research+Inc
    Average 92 stars, based on 1 article reviews
    edta plasma tissue plasminogen activator tpa molecular innovations ipctpakta - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier
    plasminogen activator inhibitor type 1 pai 1 kit  (R&D Systems)
    94
    R&D Systems plasminogen activator inhibitor type 1 pai 1 kit
    Plasminogen Activator Inhibitor Type 1 Pai 1 Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm41917468-33-23-33?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    plasminogen activator inhibitor type 1 pai 1 kit - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    human pai 1 sandwich elisa kit  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology human pai 1 sandwich elisa kit
    Human Pai 1 Sandwich Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm41744606-77-11-17?v=Elabscience+Biotechnology
    Average 94 stars, based on 1 article reviews
    human pai 1 sandwich elisa kit - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    edta plasma plasminogen activator inhibitor 1 pai 1 molecular innovations  (Innovative Research Inc)
    92
    Innovative Research Inc edta plasma plasminogen activator inhibitor 1 pai 1 molecular innovations
    Edta Plasma Plasminogen Activator Inhibitor 1 Pai 1 Molecular Innovations, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm41693475-83-72-78?v=Innovative+Research+Inc
    Average 92 stars, based on 1 article reviews
    edta plasma plasminogen activator inhibitor 1 pai 1 molecular innovations - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier
    plasminogen activator inhibitor 1  (Innovative Research Inc)
    94
    Innovative Research Inc plasminogen activator inhibitor 1
    Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
    Plasminogen Activator Inhibitor 1, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pmc12829123-47-38-43?v=Innovative+Research+Inc
    Average 94 stars, based on 1 article reviews
    plasminogen activator inhibitor 1 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    active plasminogen activator inhibitor 1 pai 1  (Innovative Research Inc)
    93
    Innovative Research Inc active plasminogen activator inhibitor 1 pai 1
    Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
    Active Plasminogen Activator Inhibitor 1 Pai 1, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/10__1182_slash_blood___2025___5252-6-17-40?v=Innovative+Research+Inc
    Average 93 stars, based on 1 article reviews
    active plasminogen activator inhibitor 1 pai 1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    plasminogen activator inhibitor 1 pai 1  (R&D Systems)
    95
    R&D Systems plasminogen activator inhibitor 1 pai 1
    Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
    Plasminogen Activator Inhibitor 1 Pai 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm41105609-96-41-59?v=R%26D+Systems
    Average 95 stars, based on 1 article reviews
    plasminogen activator inhibitor 1 pai 1 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    murine plasminogen activator inhibitor type 1 pai 1 elisa  (Innovative Research Inc)
    93
    Innovative Research Inc murine plasminogen activator inhibitor type 1 pai 1 elisa
    Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
    Murine Plasminogen Activator Inhibitor Type 1 Pai 1 Elisa, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pai+1+inhibitor+activity/pm24053625__es403146c_si_001-71-0-14?v=Innovative+Research+Inc
    Average 93 stars, based on 1 article reviews
    murine plasminogen activator inhibitor type 1 pai 1 elisa - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator inhibitor 1 (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.

    Journal: Research and Practice in Thrombosis and Haemostasis

    Article Title: Comparison of changes in blood cells and hemostatic biomarkers in mouse xenograft models of acute myeloid leukemia and acute promyelocytic leukemia

    doi: 10.1016/j.rpth.2025.103319

    Figure Lengend Snippet: Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator inhibitor 1 (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.

    Article Snippet: Levels of different biomarkers in plasma were measured using commercial enzyme-linked immunosorbent assays: TAT (Siemens, cat number OWMG15), fibrinogen (Immunology Consultation Laboratory Inc, cat number E-90FIB), PAP (MyBioSource, cat number MBS2512896), D-dimer (Diagnostica Stago, cat number 00947), and plasminogen activator inhibitor 1 (PAI-1; Molecular Innovations, cat number IMSPAI1KTA). cfDNA was measured using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific, cat number P11496).

    Techniques: Control